臨床泌尿器科72巻7号

2018年06月発行

特集 エキスパートが本音で語る! 膀胱癌診療の最前線 〈膀胱癌治療の最前線〉

膀胱癌に対する全身化学療法

著者： 北村寛¹

所属機関： ¹富山大学大学院医学薬学研究部腎泌尿器科学講座

ページ範囲：P.554 - P.560

▶ポイント

・現時点では，切除不能または転移を有する膀胱癌に対する一次治療の標準はシスプラチンベースの全身化学療法である．

・Neoadjuvant化学療法には生存期間延長効果のエビデンスがある．Adjuvant化学療法には十分なエビデンスはないが，有用性はあると考えてよい．

・現在実施中の免疫チェックポイント阻害薬に関する臨床試験の結果により，今後化学療法のポジションが変化する可能性がある．

参考文献

1） Sternberg CN, Yagoda A, Scher HI, et al : Preliminary results of M-VAC （methotrexate, vinblastine, doxorubicin and cisplatin） for transitional cell carcinoma of the urothelium. J Urol 133 : 403─407, 1985

2） Sternberg CN, Yagoda A, Scher HI, et al : Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64 : 2448─2458, 1989

3） Loehrer PJ, Einhorn LH, Elson PJ, et al : A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma : a cooperative group study. J Clin Oncol 10 : 1066─1073, 1992

4） Logothetis CJ, Dexeus FH, Finn L, et al : A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8 : 1050─1055, 1990

5） von der Maase H, Hansen SW, Roberts JT, et al : Gemcitabine and cisplatin versus Methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer : results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17 : 3068─3077, 2000

6） von der Maase H, Sengelov L, Roberts JT, et al : Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 : 4602─4608, 2005

7） 日本泌尿器科学会・日本放射線腫瘍学会 （編） : 膀胱癌診療ガイドライン2015年版. 医学図書出版社, 東京, 2015

8） NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. Version 3.2018（https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf）

9） Sternberg CN, de Mulder PH, Schornagel JH, et al : Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin （MVAC） chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors : European Organization for Research and Treatment of Cancer protocol No. 30924. J Clin Oncol 19 : 2638─2646, 2001

10） Sternberg CN, de Mulder P, Schornagel JH, et al : Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42 : 50─54, 2006

11） Bellmunt J, Théodore C, Demkov T, et al : Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27 : 4454─4461, 2009

12） Petrylak DP, de Wit R, Chi KN, et al : Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy （RANGE） : a randomised, double-blind, phase 3 trial. Lancet 390 : 2266─2277, 2017

13） Sonpavde G, Pond GR, Choueiri TK, et al : Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. Eur Urol 69 : 634─641, 2016

14） Salah S, Lee JL, Rozzi A, et al : Second-Line Chemotherapy for Metastatic Urothelial Carcinoma : Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model. Clin Genitourin Cancer 14 : 255─260, 2016

15） Grossman HB, Natale RB, Tangen CM, et al : Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349 : 859─866, 2003

16） International Collaboration of Trialists ; Medical Research Council Advanced Bladder Cancer Working Party （now the National Cancer Research Institute Bladder Cancer Clinical Studies Group）; European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group ; Australian Bladder Cancer Study Group ; National Cancer Institute of Canada Clinical Trials Group ; Finnbladder ; Norwegian Bladder Cancer Study Group ; Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer : long-term results of the BA06 30894 Trial. J Clin Oncol 29 : 2171─2177, 2011

17） Kitamura H, Tsukamoto T, Shibata T, et al : Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer : Japan Clinical Oncology Group Study JCOG0209. Ann Oncol 25 : 1192─1198, 2014

18） van de Putte EEF, Mertens LS, Meijer RP, et al : Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer : efficacy and safety compared with classic MVAC and gemcitabine/cisplatin. World J Urol 34 : 157─162, 2016

19） Zargar H, Shah JB, van Rhijn BW, et al : Neoadjuvant Dose Dense Mvac versus Gemcitabine and Cisplatin in Patients with Ct3-4An0M0 Bladder Cancer Treated with Radical Cystectomy. J Urol 199 : 1452─1458, 2018

20） Sternberg CN, Skoneczna I, Kerst JM, et al : Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N＋M0 urothelial carcinoma of the bladder （EORTC 30994） : an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16 : 76─86, 2015

21） Galsky MD, Stensland KD, Moshier E, et al : Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. J Clin Oncol 34 : 825─832, 2016

22） Seisen T, Jamzadeh A, Leow JJ, et al : Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated with Neoadjuvant Chemotherapy. JAMA Oncol 4 : 225─229, 2018

23） De Santis M, Bellmunt J, Mead G, et al : Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy : EORTC study 30986. J Clin Oncol 30 : 191─199, 2012

24） Japan Clinical Oncology GroupポリシーNo.39. 高齢者研究. 2016.5.27 （http://www.jcog.jp/basic/policy/A_020_0010_39.pdf）